Grade Group (prostatectomy

(1)

Supplemental Table 1 Demographic and clinicopathological characteristics of 103 non-NHT patients and 103 NHT patients after propensity score matching

Patients without NHT Patients with NHT

N=103 N=103

PSA at diagnosis (ng/mL) p=0.316

<10 64 (62%) 55 (53%)

10-20 23 (22%) 24 (23%)

>20 16 (16%) 24 (23%)

Grade Group (needle biopsy) p=0.762

1 23 (22%) 17 (17%)

2 30 (29%) 31 (30%)

3 19 (18%) 22 (21%)

4 20 (19%) 18 (17%)

5 11 (11%) 15 (15%)

Clinical stage p=0.506

cT1c 11 (11%) 11 (11%)

cT2 79 (77%) 73 (71%)

cT3a 13 (10%) 19 (18%)

Type of NHT -

LHRH agonist - 65 (63%)

CAB - 38 (37%)

Duration of NHT (months) -

3 - 50 (49%)

4-6 - 42 (41%)

7-12 - 11 (11%)

Grade Group (prostatectomy) -

1 14 (14%) -

2 15 (15%) -

3 48 (47%) -

4 13 (13%) -

5 13 (13%) -

Pathological stage p=0.041

pT2 49 (48%) 67 (66%)

pT3a 42 (41%) 28 (27%)

pT3b 12 (12%) 8 (8%)

undeterminable 1

Margin status p<0.001

negative 40 (39%) 59 (58%)

positive 63 (61%) 43 (42%)

undeterminable 1

(2)

NHT; neoadjuvant hormonal therapy, PSA; prostate-specific antigen, LHRH; luteinizing hormone releasing hormone, CAB; combined antiandrogen blockade